The current and changing role of glucagon-like peptide-1 receptor agonists in knee osteoarthritis.
作者信息
Holleman Anne D, Katz Jeffrey N
机构信息
Department of Orthopedics, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
出版信息
Osteoarthr Cartil Open. 2025 Apr 12;7(3):100611. doi: 10.1016/j.ocarto.2025.100611. eCollection 2025 Sep.
Abstract
摘要
相似文献
1
The current and changing role of glucagon-like peptide-1 receptor agonists in knee osteoarthritis.
Osteoarthr Cartil Open. 2025 Apr 12;7(3):100611. doi: 10.1016/j.ocarto.2025.100611. eCollection 2025 Sep.
2
The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists.
J Arthroplasty. 2024 Oct;39(10):2433-2439.e1. doi: 10.1016/j.arth.2024.06.008. Epub 2024 Jun 8.
3
Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.
Ann Rheum Dis. 2023 Sep;82(9):1218-1226. doi: 10.1136/ard-2023-223845. Epub 2023 May 31.
4
Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon-like peptide-1 agonists.
Clin Obes. 2025 Feb;15(1):e12700. doi: 10.1111/cob.12700. Epub 2024 Aug 16.
5
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohorts Retrospective Study.
Diabetes Metab Res Rev. 2025 Jul;41(5):e70051. doi: 10.1002/dmrr.70051.
6
The Impact of Contemporary Glucagon-like Peptide-1 Receptor Agonists on the Onset, Severity, and Conversion to Arthroplasty in Hip and Knee Osteoarthritis.
Orthop J Sports Med. 2025 Jan 13;13(1):23259671241297157. doi: 10.1177/23259671241297157. eCollection 2025 Jan.
7
Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.
Arthroplast Today. 2024 Jun 27;27:101327. doi: 10.1016/j.artd.2024.101327. eCollection 2024 Jun.
8
Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study.
Medicine (Baltimore). 2025 Feb 7;104(6):e41243. doi: 10.1097/MD.0000000000041243.
9
Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
Anaesthesia. 2024 Jul;79(7):735-747. doi: 10.1111/anae.16306. Epub 2024 May 13.
10
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22.
本文引用的文献
1
Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies.
Osteoarthr Cartil Open. 2025 Jan 28;7(1):100567. doi: 10.1016/j.ocarto.2025.100567. eCollection 2025 Mar.
2
Mapping the effectiveness and risks of GLP-1 receptor agonists.
Nat Med. 2025 Mar;31(3):951-962. doi: 10.1038/s41591-024-03412-w. Epub 2025 Jan 20.
3
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Metabolism. 2024 Dec;161:156057. doi: 10.1016/j.metabol.2024.156057. Epub 2024 Oct 30.
4
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
N Engl J Med. 2024 Oct 31;391(17):1573-1583. doi: 10.1056/NEJMoa2403664.
5
Weight Loss-Induced Muscle Mass Loss.
JAMA. 2024 Sep 23. doi: 10.1001/jama.2024.17212.
6
Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes.
BMC Musculoskelet Disord. 2024 Jul 30;25(1):601. doi: 10.1186/s12891-024-07640-6.
7
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.
8
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.
EClinicalMedicine. 2024 Feb 19;69:102475. doi: 10.1016/j.eclinm.2024.102475. eCollection 2024 Mar.
9
Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.
Ann Rheum Dis. 2023 Sep;82(9):1218-1226. doi: 10.1136/ard-2023-223845. Epub 2023 May 31.
10
Effect of Diet and Exercise on Knee Pain in Patients With Osteoarthritis and Overweight or Obesity: A Randomized Clinical Trial.
JAMA. 2022 Dec 13;328(22):2242-2251. doi: 10.1001/jama.2022.21893.
Zotero 插件